Instem, an IT solutions provider focused on global early development healthcare, said today it expanded into the early phase clinical trials market by acquiring Logos Technologies and its ...

KALOS and LOGOS Phase III trials. KALOS and LOGOS are replicate confirmatory, randomized, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Mandal, Ananya. (2023, January 02). What is a Phase 4 Clinical Trial?.

Clinical trials often can take years, Schacker said, but these may take less time in part because the process of finding patients to participate is happening quickly.

Logos Technologies’ ALPHADAS Solution Suite is Market Leading, e-source Data Capture System and Site Automation Software for Managing Early Phase Clinical Studies May 13, 2013 08:30 AM Eastern ...

Pfizer-BioNTech said Thursday that it is beginning clinical trials of its Covid-19 vaccine in pregnant women, the first such trials to include expectant mothers in the U.S. The drugmaker aims to ...

Instem has bought a ticket to play a larger role in the market for early-stage clinical trials. The provider of IT solutions has acquired Logos Technologies, which provides electronic data-capture ...

KALOS and LOGOS Phase III trials. KALOS and LOGOS are replicate confirmatory, randomized, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Mandal, Ananya. (2023, January 02). What is a Phase 2 Clinical Trial?.

KALOS and LOGOS Phase III trials. KALOS and LOGOS are replicate confirmatory, randomized, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials ...

KALOS and LOGOS Phase III trials KALOS and LOGOS are replicate confirmatory, randomized, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials to ...

WILMINGTON, Del., May 02, 2025--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination ...